- Home
- ARGX vs TFC Comparison
ARGX vs TFC Comparison
Compare ARGX & TFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- TFC
- Stock Information
- Founded
- ARGX 2008
- TFC 1872
- Country
- ARGX Netherlands
- TFC United States
- Employees
- ARGX N/A
- TFC N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- TFC Major Banks
- Sector
- ARGX Health Care
- TFC Finance
- Exchange
- ARGX Nasdaq
- TFC Nasdaq
- Market Cap
- ARGX 51.1B
- TFC 59.3B
- IPO Year
- ARGX 2017
- TFC N/A
- Fundamental
- Price
- ARGX $832.35
- TFC $44.06
- Analyst Decision
- ARGX Strong Buy
- TFC Buy
- Analyst Count
- ARGX 17
- TFC 14
- Target Price
- ARGX $866.53
- TFC $50.00
- AVG Volume (30 Days)
- ARGX 376.8K
- TFC 9.4M
- Earning Date
- ARGX 10-30-2025
- TFC 10-17-2025
- Dividend Yield
- ARGX N/A
- TFC 4.72%
- EPS Growth
- ARGX N/A
- TFC N/A
- EPS
- ARGX 23.27
- TFC 3.73
- Revenue
- ARGX $3,683,281,000.00
- TFC $18,280,000,000.00
- Revenue This Year
- ARGX $85.93
- TFC $81.81
- Revenue Next Year
- ARGX $35.17
- TFC $4.53
- P/E Ratio
- ARGX $33.14
- TFC $11.80
- Revenue Growth
- ARGX 92.98
- TFC 64.26
- 52 Week Low
- ARGX $510.06
- TFC $33.56
- 52 Week High
- ARGX $855.46
- TFC $49.06
- Technical
- Relative Strength Index (RSI)
- ARGX 62.13
- TFC 49.04
- Support Level
- ARGX $749.75
- TFC $43.66
- Resistance Level
- ARGX $850.66
- TFC $44.94
- Average True Range (ATR)
- ARGX 24.01
- TFC 0.80
- MACD
- ARGX -3.37
- TFC 0.10
- Stochastic Oscillator
- ARGX 78.14
- TFC 73.69
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
About TFC Truist Financial Corporation
Based in Charlotte, North Carolina, Truist is the combination of BB&T and SunTrust. Truist is a regional bank with a presence primarily in the Southeastern United States. In addition to commercial banking, retail banking, and investment banking operations, the company operates several nonbank segments.